"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1559-1569.
-
Nanoparticle-based targeted delivery of pentagalloyl glucose reverses elastase-induced abdominal aortic aneurysm and restores aorta to the healthy state in mice. PLoS One. 2020; 15(3):e0227165.
-
Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis. Inflammation. 2016 Aug; 39(4):1345-53.
-
Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles. Circ Res. 2015 Nov 06; 117(11):e80-9.
-
Human anti-a3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis. Am J Physiol Renal Physiol. 2015 Oct 15; 309(8):F680-4.
-
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. J Clin Oncol. 2015 May 10; 33(14):1609-19.
-
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014 Nov; 66(11):3096-104.
-
Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Cancer. 2014 Dec 15; 120(24):4006-7.
-
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014 Aug 15; 120(16):2464-71.
-
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.